Nanoparticle-Sirna: A Potential Strategy for Ovarian Cancer Therapy?

Science Communicator Platform

Share By

Nanoparticle-Sirna: A Potential Strategy for Ovarian Cancer Therapy? Publisher Pubmed

Aghamiri S¹ ; Mehrjardi KF^{2, 3} ; Shabani S⁴ ; Keshavarzfathi M^{3, 5} ; Kargar S⁶ ; Rezaei N⁷

Source: Nanomedicine Published:2019

Abstract

Ovarian cancer is one of the most common causes of mortality throughout the world. Unfortunately, chemotherapy has failed to cure advanced cancers developing multidrug resistance (MDR). Moreover, it has critical side effects because of nonspecific toxicity. Thanks to specific silencing of oncogenes and MDR-associated genes, nano-siRNA drugs can be a great help address the limitations of chemotherapy. Here, we review the current advances in nanoparticle-mediated siRNA delivery strategies such as polymeric- and lipid-based systems, rigid nanoparticles and nanoparticles coupled to specific ligand systems. Nanoparticle-based codelivery of anticancer drugs and siRNA targeting various mechanisms of MDR is a cutting-edge strategy for ovarian cancer therapy, which is completely discussed in this review. © 2019 Future Medicine Ltd.

Related Docs

View other Related Docs

1. Targeting Sirna in Colorectal Cancer Therapy: Nanotechnology Comes Into View, Journal of Cellular Physiology (2019)

2. Stimuli-Responsive Mesoporous Silica Nps As Non-Viral Dual Sirna/Chemotherapy Carriers for Triple Negative Breast Cancer, Molecular Therapy Nucleic Acids (2017)

3. Small Interfering Rnas (Sirnas) in Cancer Therapy: A Nano-Based Approach, International journal of nanomedicine (2019)

Experts (# of related papers)

View all Related Experts

Fatemeh Atyabi (7)

Rassoul Dinarvand (3)

Other Related Docs

4. The Use of Nanoparticles As a Promising Therapeutic Approach in Cancer Immunotherapy, Artificial Cells# Nanomedicine and Biotechnology (2016)

5. Dual Drug Delivery System of Plga Nanoparticles to Reverse Drug Resistance by Altering Bax/Bcl-2, Journal of Drug Delivery Science and Technology (2018)

6. Boosting Breast Cancer Immunotherapy Through Targeted Sirna Delivery and Sequential Chemotherapy, Journal of Drug Targeting (2025)

7. Targeted Cancer Therapy: Review Article, Tehran University Medical Journal (2018)

8. Bacteria and Archaea: A New Era of Cancer Therapy, Journal of Controlled Release (2021)

9. Recent Advances in Engineering Chitosan-Based Nanoplatforms in Biotherapeutic Multi-Delivery for Multi-Targeted Disease Treatments: Promises and Outlooks, Colloids and Interface Science Communications (2025)

10. A Potential Role for Oridonin in Cancer Control: Mechanisms of Autophagy and Apoptosis, Current Cancer Drug Targets (2025)

11. Theranostic Silk Sericin/Spion Nanoparticles for Targeted Delivery of Ror1 Sirna: Synthesis, Characterization, Diagnosis and Anticancer Effect on Triple-Negative Breast Cancer, International Journal of Biological Macromolecules (2022)

12. Apoptotic Effects of Mucin1 Aptamer-Conjugated Nanoparticles Containing Docetaxel and C-Met Sirna on Skbr3 Human Metastatic Breast Cancer Cells, Veterinary World (2019)

13. The Therapeutic Effects of Berberine for Gastrointestinal Cancers, Asia-Pacific Journal of Clinical Oncology (2024)

14. Delivery of Egfr-Sirna to Prostatic Cancerous Cells Based on Polydopamine Coated Gold Nanoparticles, Journal of Drug Delivery Science and Technology (2023)

15. Combination Therapy of Breast Cancer by Codelivery of Doxorubicin and Survivin Sirna Using Polyethylenimine Modified Silk Fibroin Nanoparticles, ACS Biomaterials Science and Engineering (2021)

16. Liposome-Engineered Therapeutics: A Promising Frontier in Ovarian Cancer Treatment, Tissue and Cell (2026)

17. Nanovehicles for Co-Delivery of Anticancer Agents, Drug Discovery Today (2020)

18. Metallic Nanoparticles for the Modulation of Tumor Microenvironment; a New Horizon, Frontiers in Bioengineering and Biotechnology (2022)

19. Co-Delivery of Il17rb Sirna and Doxorubicin by Chitosan-Based Nanoparticles for Enhanced Anticancer Efficacy in Breast Cancer Cells, Biomedicine and Pharmacotherapy (2016)

20. Chemotherapeutic Activity of Silymarin Combined With Doxorubicin Liposomes in 4T1 Breast Cancer Cells, Nanomedicine Research Journal (2019)

Style	Citing Format
MLA	Aghamiri S, et al.. "Nanoparticle-Sirna: A Potential Strategy for Ovarian Cancer Therapy?." Nanomedicine, vol. 14, no. 15, 2019, pp. 2083-2100.
APA	Aghamiri S, Mehrjardi KF, Shabani S, Keshavarzfathi M, Kargar S, Rezaei N (2019). Nanoparticle-Sirna: A Potential Strategy for Ovarian Cancer Therapy?. Nanomedicine, 14(15), 2083-2100.
Chicago	Aghamiri S, Mehrjardi KF, Shabani S, Keshavarzfathi M, Kargar S, Rezaei N. "Nanoparticle-Sirna: A Potential Strategy for Ovarian Cancer Therapy?." Nanomedicine 14, no. 15 (2019): 2083-2100.
Harvard	Aghamiri S et al. (2019) 'Nanoparticle-Sirna: A Potential Strategy for Ovarian Cancer Therapy?', Nanomedicine, 14(15), pp. 2083-2100.
Vancouver	Aghamiri S, Mehrjardi KF, Shabani S, Keshavarzfathi M, Kargar S, Rezaei N. Nanoparticle-Sirna: A Potential Strategy for Ovarian Cancer Therapy?. Nanomedicine. 2019;14(15):2083-2100.
BibTex	@article{ author = {Aghamiri S and Mehrjardi KF and Shabani S and Keshavarzfathi M and Kargar S and Rezaei N}, title = {Nanoparticle-Sirna: A Potential Strategy for Ovarian Cancer Therapy?}, journal = {Nanomedicine}, volume = {14}, number = {15}, pages = {2083-2100}, year = {2019} }
RIS	TY - JOUR AU - Aghamiri S AU - Mehrjardi KF AU - Shabani S AU - Keshavarzfathi M AU - Kargar S AU - Rezaei N TI - Nanoparticle-Sirna: A Potential Strategy for Ovarian Cancer Therapy? JO - Nanomedicine VL - 14 IS - 15 SP - 2083 EP - 2100 PY - 2019 ER -

Science Communicator Platform

Authors

Abstract